drugset / Trial / NCT00219037
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
RandomizedParallel-groupSingle-blindTreatment
Summary
Assess the long-term safety and tolerability of aliskiren, with the optional addition of HCTZ, in patients with essential hypertension, to ensure long term blood pressure control and protect against end organ damage.
Timeline
- Start
- 2004-06
- Primary completion
- 2005-10
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aliskiren | Small molecule | 150 mg | Oral |
| Subject | Aliskiren | Small molecule | 300 mg | Oral |